Laniquidar

• CAT Number: I007616
• CAS Number: 197509-46-9
• Molecular Formula: C37H36N4O3
• Molecular Weight: 584.72
• Purity: ≥95%
• Synonyms: Laniquidar; R101933; R 101933; R-101933.;methyl 11-(1-(4-(quinolin-2-ylmethoxy)phenethyl)piperidin-4-ylidene)-6,11-dihydro-5H-benzo[d]imidazo[1,2-a]azepine-3-carboxylate
• Target: P-glycoprotein
• Solubility: Soluble in DMSO, not in water
• Storage: 0 - 4°C for short term , or -20°C for long term.
• IUPAC Name: methyl 11-[1-[2-[4-(quinolin-2-ylmethoxy)phenyl]ethyl]piperidin-4-ylidene]-5,6-dihydroimidazo[2,1-b][3]benzazepine-3-carboxylate
• InChI: InChI=1S/C37H36N4O3/c1-43-37(42)34-24-38-36-35(32-8-4-2-6-27(32)19-23-41(34)36)29-17-21-40(22-18-29)20-16-26-10-14-31(15-11-26)44-25-30-13-12-28-7-3-5-9-33(28)39-30/h2-15,24H,16-23,25H2,1H3
• InChIKey: TULGGJGJQXESOO-UHFFFAOYSA-N
• SMILES: COC(=O)C1=CN=C2N1CCC3=CC=CC=C3C2=C4CCN(CC4)CCC5=CC=C(C=C5)OCC6=NC7=CC=CC=C7C=C6

Laniquidar is a potent inhibitor of P-glycoprotein (P-gp), a membrane transporter protein involved in multidrug resistance (MDR) in cancer cells. By blocking P-gp, laniquidar prevents the efflux of chemotherapeutic agents from cancer cells, thereby enhancing the intracellular concentration and efficacy of these drugs. This compound is primarily used in cancer research to overcome drug resistance and improve the effectiveness of chemotherapy in resistant tumors. Laniquidar’s ability to inhibit P-gp makes it a valuable tool for exploring new therapeutic strategies targeting MDR in cancer treatment.